
Healthcare / Pharmaceuticals · NSE / BSE
Amanta Healthcare Limited, founded in December 1994, is a pharmaceutical company engaged in developing, manufacturing, and marketing sterile liquid products, mainly parenteral formulations, using advanced Aseptic Blow-Fill-Seal and Injection Stretch Blow Moulding technologies. The company also produces medical devices and offers a wide range of products including IV fluids, diluents, ophthalmic solutions, respiratory care products, irrigation solutions, first-aid items, and eye lubricants. Its business is divided into three units: national sales, international sales, and product partnerships with Indian and global pharmaceutical companies. Amanta manufactures over 45 generic products, distributed across India through 320 distributors and stockists, while also exporting to Africa, Latin America, the UK, and other regions. Its products are registered in 19 countries, and in Fiscal 2025, it exported branded products to 21 countries. As of March 31, 2025, the company employed 1,718 people across its formulation, development, and quality laboratories.
Price Band
₹120 – ₹126
Issue Size
₹126 Cr
Lot Size
119 shares
GMP
+7.1%
Est. Listing
₹135
at current GMP
Subscribed
82.61x
overall
Open
1 Sep 2025
Close
3 Sep 2025
Allotment
4 Sep 2025
Refund
5 Sep 2025
Demat Credit
6 Sep 2025
Listing
9 Sep 2025
Designated Registrar: Link Intime India Private Limited
Allotment Date
4 Sep 2025
Basis finalization
Refunds Initiate
5 Sep 2025
Mandate release
Demat Credit
6 Sep 2025
Shares in demat
Listing Debut
9 Sep 2025
Trading begins
Amanta Healthcare Limited is bringing an initial public offering (IPO) in the Healthcare / Pharmaceuticals sector with an aggregate issue size of ₹126 Crores. The shares are offered at a price band of ₹120 to ₹126 per equity share on NSE and BSE. Currently, investors are tracking the grey market premium (GMP) and institutional subscription multiples closely across BSE and NSE portals.
The public offer consists of a fresh issue and offer-for-sale structured under SEBI regulations. Bidding is open to Qualified Institutional Buyers (QIB), Non-Institutional Bidders (NII/HNI), and Retail Individual Investors (RII). Applications can be submitted online using ASBA or UPI mandate through certified stock brokers and net banking portals.
Following the close of bidding on 2025-09-03, the basis of allotment is scheduled to be finalized on 2025-09-04. Investors can verify their application status online by submitting their PAN card number, Application Number, or DP Client ID on the registrar's official portal (Link Intime India Private Limited) or the BSE allotment checking window.
Allotment records are updated in batches. If the status is not yet available, please wait a few hours until the basis of allotment is fully finalized.
Since funds are blocked under ASBA/UPI, the bank will automatically release the blocked hold on your funds upon receipt of revocation instructions from the sponsor bank.